Buyers should specify active ingredients, dosage forms, packaging requirements (such as volume, bottle or box type), target market regulatory standards (such as GMP or CEP), and estimated order volumes.
Category market report
Ear, Nose & Throat Drugs
Total suppliers
6,843+
Total Chinese suppliers export
$9.3B+
Recommended
High-quality suppliers related to Ear, Nose & Throat Drugs.
Suppliers
Find more suppliers who may be worth contacting.
Top suppliers
Suppliers in this category.
- Transactions
1,897
2018-012022-032026-08Transaction trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 4
- 2018-02: 2
- 2018-03: 3
- 2018-04: 4
- 2018-05: 3
- 2018-06: 10
- 2018-07: 5
- 2018-09: 10
- 2018-10: 2
- 2018-11: 1
- 2018-12: 1
- 2019-01: 32
- 2019-02: 19
- 2019-03: 17
- 2019-04: 13
- 2019-05: 19
- 2019-06: 16
- 2019-07: 9
- 2019-08: 5
- 2019-09: 4
- 2019-10: 7
- 2019-11: 13
- 2019-12: 15
- 2020-01: 24
- 2020-02: 1
- 2020-03: 18
- 2020-04: 30
- 2020-05: 27
- 2020-06: 14
- 2020-07: 13
- 2020-08: 38
- 2020-09: 4
- 2020-10: 21
- 2020-11: 28
- 2020-12: 16
- 2021-01: 9
- 2021-02: 42
- 2021-03: 23
- 2021-04: 20
- 2021-05: 44
- 2021-06: 23
- 2021-07: 19
- 2021-08: 33
- 2021-09: 15
- 2021-10: 46
- 2021-11: 27
- 2021-12: 22
- 2022-01: 43
- 2022-02: 9
- 2022-03: 22
- 2022-04: 30
- 2022-05: 24
- 2022-06: 26
- 2022-07: 19
- 2022-08: 18
- 2022-09: 19
- 2022-10: 34
- 2022-11: 12
- 2022-12: 37
- 2023-01: 13
- 2023-02: 19
- 2023-03: 51
- 2023-04: 22
- 2023-05: 12
- 2023-06: 26
- 2023-07: 23
- 2023-08: 17
- 2023-09: 45
- 2023-10: 10
- 2023-11: 32
- 2023-12: 15
- 2024-02: 28
- 2024-03: 12
- 2024-05: 31
- 2024-06: 18
- 2024-07: 16
- 2024-08: 6
- 2024-09: 15
- 2024-10: 16
- 2024-11: 11
- 2024-12: 14
- 2025-01: 21
- 2025-02: 14
- 2025-03: 19
- 2025-04: 13
- 2025-05: 9
- 2025-06: 11
- 2025-07: 20
- 2025-08: 17
- 2025-09: 13
- 2025-10: 7
- 2025-11: 13
- 2025-12: 16
- 2026-01: 21
- 2026-03: 13
- 2026-04: 49
- 2026-05: 33
- 2026-06: 25
- 2026-07: 28
- 2026-08: 14
- Amount
4,100,621.13
2018-012022-032026-08Amount trend for Astrazeneca Pharmaceutical Co., Ltd.
- 2018-01: 19.5M
- 2018-02: 23.3K
- 2018-03: 613.5K
- 2018-04: 401K
- 2018-05: 53.6K
- 2018-06: 195.8K
- 2018-07: 174.2K
- 2018-09: 1.4M
- 2018-10: 143.4K
- 2018-11: 27.6K
- 2018-12: 23K
- 2019-01: 40.7B
- 2019-02: 2.8M
- 2019-03: 2.4M
- 2019-04: 1.7M
- 2019-05: 2.6M
- 2019-06: 3.1M
- 2019-07: 1.8M
- 2019-08: 840.4K
- 2019-09: 772.1K
- 2019-10: 2.5M
- 2019-11: 2M
- 2019-12: 1.8M
- 2020-01: 7M
- 2020-02: 9,942.19
- 2020-03: 3.1M
- 2020-04: 4.1M
- 2020-05: 4.5M
- 2020-06: 5.9M
- 2020-07: 2.1M
- 2020-08: 7.6M
- 2020-09: 281.4K
- 2020-10: 1.8M
- 2020-11: 2.3M
- 2020-12: 2.1M
- 2021-01: 927.7K
- 2021-02: 5.9M
- 2021-03: 3M
- 2021-04: 2.8M
- 2021-05: 6.3M
- 2021-06: 4.1M
- 2021-07: 2.5M
- 2021-08: 4M
- 2021-09: 3.4M
- 2021-10: 7M
- 2021-11: 3.9M
- 2021-12: 4M
- 2022-01: 8.5M
- 2022-02: 2.3M
- 2022-03: 2.2M
- 2022-04: 5.2M
- 2022-05: 2.8M
- 2022-06: 4.1M
- 2022-07: 3.3M
- 2022-08: 2.1M
- 2022-09: 2.8M
- 2022-10: 5.3M
- 2022-11: 2M
- 2022-12: 5.9M
- 2023-01: 1.2M
- 2023-02: 3.3M
- 2023-03: 6.5M
- 2023-04: 3.4M
- 2023-05: 3.1M
- 2023-06: 3.4M
- 2023-07: 2.5M
- 2023-08: 2.8M
- 2023-09: 6.7M
- 2023-10: 1.9M
- 2023-11: 5.4M
- 2023-12: 3.1M
- 2024-02: 8.1M
- 2024-03: 3.1M
- 2024-05: 5.5M
- 2024-06: 3.3M
- 2024-07: 3M
- 2024-08: 1.3M
- 2024-09: 2.5M
- 2024-10: 2.2M
- 2024-11: 2M
- 2024-12: 1.8M
- 2025-01: 4.7M
- 2025-02: 1M
- 2025-03: 2.5M
- 2025-04: 2.9M
- 2025-05: 2.5M
- 2025-06: 1.9M
- 2025-07: 3M
- 2025-08: 1.3M
- 2025-09: 2.8M
- 2025-10: 661.9K
- 2025-11: 2M
- 2025-12: 3.1M
- 2026-01: 1.9M
- 2026-03: 697.5K
- 2026-04: 3.1M
- 2026-05: 1.7M
- 2026-06: 1.3M
- 2026-07: 799.3K
- 2026-08: 117.8K
- Main export countries
- India (0.6%)
- Sri Lanka (0%)
- Namibia (0%)
- Mexico (99.3%)
- Transactions
47
2019-012020-102021-09Transaction trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 32
- 2019-11: 2
- 2020-04: 2
- 2020-05: 1
- 2020-06: 1
- 2020-10: 1
- 2021-03: 2
- 2021-04: 1
- 2021-05: 1
- 2021-07: 1
- 2021-08: 1
- 2021-09: 2
- Amount
559,462.81
2019-012020-102021-09Amount trend for Puyang Hotway Pharmacy Co., Ltd.
- 2019-01: 5.6B
- 2019-11: 24.9K
- 2020-04: 22.1K
- 2020-05: 11.8K
- 2020-06: 12.3K
- 2020-10: 11.9K
- 2021-03: 24.6K
- 2021-04: 12.5K
- 2021-05: 12.7K
- 2021-07: 12.5K
- 2021-08: 12.5K
- 2021-09: 25.3K
- Main export countries
- Indonesia (100%)
- Transactions
2,150
2018-012022-072026-09Transaction trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 9
- 2018-02: 12
- 2018-03: 11
- 2018-04: 7
- 2018-05: 11
- 2018-06: 19
- 2018-07: 14
- 2018-08: 21
- 2018-09: 20
- 2018-10: 15
- 2018-11: 15
- 2018-12: 10
- 2019-01: 21
- 2019-02: 4
- 2019-03: 10
- 2019-04: 12
- 2019-05: 19
- 2019-06: 9
- 2019-07: 7
- 2019-08: 17
- 2019-09: 14
- 2019-10: 9
- 2019-11: 22
- 2019-12: 14
- 2020-01: 14
- 2020-02: 16
- 2020-03: 5
- 2020-05: 6
- 2020-06: 22
- 2020-08: 18
- 2020-10: 20
- 2020-11: 21
- 2020-12: 8
- 2021-02: 8
- 2021-03: 19
- 2021-04: 10
- 2021-05: 15
- 2021-06: 9
- 2021-07: 16
- 2021-08: 11
- 2021-09: 8
- 2021-10: 18
- 2021-11: 20
- 2021-12: 28
- 2022-01: 12
- 2022-02: 18
- 2022-03: 19
- 2022-05: 17
- 2022-06: 19
- 2022-07: 25
- 2022-08: 15
- 2022-09: 41
- 2022-10: 25
- 2022-11: 28
- 2022-12: 38
- 2023-01: 30
- 2023-02: 11
- 2023-03: 43
- 2023-04: 42
- 2023-05: 29
- 2023-06: 18
- 2023-07: 25
- 2023-08: 19
- 2023-09: 15
- 2023-10: 27
- 2023-11: 24
- 2023-12: 20
- 2024-01: 44
- 2024-02: 34
- 2024-03: 21
- 2024-04: 37
- 2024-05: 32
- 2024-06: 19
- 2024-07: 16
- 2024-08: 14
- 2024-09: 21
- 2024-10: 35
- 2024-11: 44
- 2024-12: 56
- 2025-01: 39
- 2025-02: 43
- 2025-03: 41
- 2025-04: 28
- 2025-05: 31
- 2025-06: 21
- 2025-07: 32
- 2025-08: 13
- 2025-09: 16
- 2025-10: 20
- 2025-11: 15
- 2025-12: 16
- 2026-01: 24
- 2026-02: 22
- 2026-03: 30
- 2026-04: 23
- 2026-05: 37
- 2026-06: 46
- 2026-07: 14
- 2026-08: 14
- 2026-09: 24
- Amount
82,855.66
2018-012022-072026-09Amount trend for Humanwell Puracap Pharmaceutical Co.
- 2018-01: 3.5M
- 2018-02: 4.8M
- 2018-03: 4.8M
- 2018-04: 1.9M
- 2018-05: 2M
- 2018-06: 5.1M
- 2018-07: 2.9M
- 2018-08: 5.5M
- 2018-09: 5.5M
- 2018-10: 4.2M
- 2018-11: 7.5M
- 2018-12: 2.4M
- 2019-01: 6.4M
- 2019-02: 1.4M
- 2019-03: 5.2M
- 2019-04: 4.2M
- 2019-05: 5.2M
- 2019-06: 3M
- 2019-07: 2.3M
- 2019-08: 5M
- 2019-09: 4.6M
- 2019-10: 3.7M
- 2019-11: 6.6M
- 2019-12: 2.5M
- 2020-01: 3.7M
- 2020-02: 5.3M
- 2020-03: 1.8M
- 2020-05: 1.9M
- 2020-06: 12.1M
- 2020-08: 5.9M
- 2020-10: 10.2M
- 2020-11: 13M
- 2020-12: 4.8M
- 2021-02: 2.9M
- 2021-03: 11.4M
- 2021-04: 4.8M
- 2021-05: 6M
- 2021-06: 5.5M
- 2021-07: 8.9M
- 2021-08: 7.6M
- 2021-09: 3.1M
- 2021-10: 9.9M
- 2021-11: 11.6M
- 2021-12: 13.5M
- 2022-01: 7.1M
- 2022-02: 12.3M
- 2022-03: 9.4M
- 2022-05: 8.1M
- 2022-06: 14.3M
- 2022-07: 16.1M
- 2022-08: 6.7M
- 2022-09: 15.5M
- 2022-10: 10.7M
- 2022-11: 12.3M
- 2022-12: 36.8M
- 2023-01: 13.5M
- 2023-02: 5.4M
- 2023-03: 17.7M
- 2023-04: 21M
- 2023-05: 11M
- 2023-06: 11.2M
- 2023-07: 9.1M
- 2023-08: 8.5M
- 2023-09: 6.3M
- 2023-10: 9.8M
- 2023-11: 9.2M
- 2023-12: 7.8M
- 2024-01: 16.7M
- 2024-02: 13.6M
- 2024-03: 6.9M
- 2024-04: 11M
- 2024-05: 10.4M
- 2024-06: 7.2M
- 2024-07: 9.3M
- 2024-08: 6.6M
- 2024-09: 5.2M
- 2024-10: 11.5M
- 2024-11: 10.1M
- 2024-12: 12.5M
- 2025-01: 10.9M
- 2025-02: 9.8M
- 2025-03: 7.5M
- 2025-04: 4.7M
- 2025-05: 7.4M
- 2025-06: 4.7M
- 2025-07: 12.4M
- 2025-08: 3.5M
- 2025-09: 5.5M
- 2025-10: 5.4M
- 2025-11: 3.7M
- 2025-12: 4.2M
- 2026-01: 6.1M
- 2026-02: 6.3M
- 2026-03: 8.5M
- 2026-04: 6.3M
- 2026-05: 16.2M
- 2026-06: 13.9M
- 2026-07: 3.7M
- 2026-08: 4.2M
- 2026-09: 6.8M
- Main export countries
- United States (99.1%)
- India (0%)
- Not available (0.9%)
Intelligence
China export momentum, destination markets, and regional demand.
China export trend
China export trend
- Date 2018-07: Value 2.8B USD
- Date 2018-08: Value 2.7B USD
- Date 2018-09: Value 2.4B USD
- Date 2018-10: Value 2.5B USD
- Date 2018-11: Value 3.1B USD
- Date 2018-12: Value 3B USD
- Date 2019-01: Value 3B USD
- Date 2019-02: Value 2B USD
- Date 2019-03: Value 3.1B USD
- Date 2019-04: Value 3.3B USD
- Date 2019-05: Value 3.7B USD
- Date 2019-06: Value 2.9B USD
- Date 2019-07: Value 3.3B USD
- Date 2019-08: Value 3.2B USD
- Date 2019-09: Value 3.2B USD
- Date 2019-10: Value 3.3B USD
- Date 2019-11: Value 3.8B USD
- Date 2019-12: Value 3.7B USD
- Date 2020-01: Value 0 USD
- Date 2020-02: Value 5.5B USD
- Date 2020-03: Value 4B USD
- Date 2020-04: Value 3.8B USD
- Date 2020-05: Value 3.1B USD
- Date 2020-06: Value 0 USD
- Date 2020-07: Value 0 USD
- Date 2020-08: Value 0 USD
- Date 2020-09: Value 3.8B USD
- Date 2020-10: Value 2.8B USD
- Date 2020-11: Value 3.3B USD
- Date 2020-12: Value 3B USD
- Date 2021-01: Value 203M USD
- Date 2021-02: Value 170M USD
- Date 2021-03: Value 201M USD
- Date 2021-04: Value 224M USD
- Date 2021-05: Value 191M USD
- Date 2021-06: Value 195M USD
- Date 2021-07: Value 215M USD
- Date 2021-08: Value 189M USD
- Date 2021-09: Value 225M USD
- Date 2021-10: Value 228M USD
- Date 2021-11: Value 222M USD
- Date 2021-12: Value 246M USD
- Date 2022-01: Value 250M USD
- Date 2022-02: Value 182M USD
- Date 2022-03: Value 266M USD
- Date 2022-04: Value 221M USD
- Date 2022-05: Value 237M USD
- Date 2022-06: Value 216M USD
- Date 2022-07: Value 237M USD
- Date 2022-08: Value 231M USD
- Date 2022-09: Value 226M USD
- Date 2022-10: Value 197M USD
- Date 2022-11: Value 249M USD
- Date 2022-12: Value 214M USD
- Date 2023-01: Value 197M USD
- Date 2023-02: Value 183M USD
- Date 2023-03: Value 223M USD
- Date 2023-04: Value 209M USD
- Date 2023-05: Value 244M USD
- Date 2023-06: Value 237M USD
- Date 2023-07: Value 188M USD
- Date 2023-08: Value 225M USD
- Date 2023-09: Value 235M USD
- Date 2023-10: Value 175M USD
- Date 2023-11: Value 215M USD
- Date 2023-12: Value 242M USD
- Date 2024-01: Value 311M USD
- Date 2024-02: Value 204M USD
- Date 2024-03: Value 282M USD
- Date 2024-04: Value 254M USD
- Date 2024-05: Value 218M USD
- Date 2024-06: Value 298M USD
- Date 2024-07: Value 262M USD
- Date 2024-08: Value 278M USD
- Date 2024-09: Value 272M USD
- Date 2024-10: Value 251M USD
- Date 2024-11: Value 291M USD
- Date 2024-12: Value 351M USD
- Date 2025-01: Value 314M USD
- Date 2025-02: Value 217M USD
- Date 2025-03: Value 297M USD
- Date 2025-04: Value 291M USD
- Date 2025-05: Value 291M USD
- Date 2025-06: Value 290M USD
- Date 2025-07: Value 313M USD
- Date 2025-08: Value 291M USD
- Date 2025-09: Value 298M USD
- Date 2025-10: Value 206M USD
- Date 2025-11: Value 317M USD
- Date 2025-12: Value 319M USD
- Date 2026-01: Value 330M USD
- Date 2026-02: Value 241M USD
- Date 2026-03: Value 294M USD
- Date 2026-04: Value 313M USD
- Date 2026-05: Value 288M USD
- Date 2026-06: Value 362M USD
- Date 2026-07: Value 340M USD
Top destinations
- Germany22.3B
- United States10.8B
- France7B
- Italy6.9B
- Sweden6.9B
- United Kingdom4.8B
- Japan3.9B
- Switzerland3.3B
- Australia3.1B
- Puerto Rico2.7B
Top destinations
- Germany: 22,334,000,000 USD
- United States: 10,827,000,000 USD
- France: 6,966,000,000 USD
- Italy: 6,949,000,000 USD
- Sweden: 6,944,000,000 USD
- United Kingdom: 4,811,000,000 USD
- Japan: 3,880,000,000 USD
- Switzerland: 3,267,000,000 USD
- Australia: 3,082,000,000 USD
- Puerto Rico: 2,732,000,000 USD
Key findings
Largest import market
22.33B USD
Germany · last 8 years
Fastest demand growth
56,399.16
Montenegro · last 8 years
Highest unit price
$592.96 /kg
Puerto Rico · +2,349.55% vs avg
Turn this market into qualified conversations.
Your agent contacts, compares, and screens the suppliers that fit.
Insights
Product insights to guide your sourcing.
Product Trends
Preservative-free nasal saline sprays and sugar-free herbal throat lozenges are experiencing rapid growth. Portable single-dose packaging and natural organic formulations are driving the recent demand surge.
Industrial Cluster Analysis
Guangdong excels in OEM/ODM throat lozenges and saline sprays for bulk orders. Shandong and Zhejiang clusters specialize in pharmaceutical-grade liquid preparations, ideal for custom contract manufacturing.
Quality Expectations
Regulated markets demand strict GMP compliance. Buyers prioritize sterile, leak-proof packaging, physiological pH matching, and stable shelf lives to ensure active ingredient efficacy and prevent microbial contamination.
What You Need to Know
Buyers can request recent Certificates of Analysis, sterile testing reports, and GMP audit records. Ordering pre-production samples allows verification of liquid consistency and spray pump mechanism performance.
Standard MOQs range from 20,000 to 50,000 units for sterile nasal/ear drops and throat lozenges. Production takes 35 to 50 days, depending on sterile batch scheduling and custom formulation testing, excluding shipping.
Buyers should budget for localized regulatory registration fees, custom formulation development, packaging mold charges, third-party lab stability testing, and temperature-controlled logistics if required.
